Metastatic renal cell carcinoma can affect the body in different ways depending on the location it has spread to. Learn more here.

Renal cell carcinoma articles from across Nature Portfolio Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The ...

Immune-checkpoint inhibitors have revolutionized the management of hepatocellular carcinoma. Currently, anti-PD-(L)-1 antibodies combined with either bevacizumab or anti-CTLA4 antibodies are the ...

Renal cell carcinoma (RCC) accounts for about 90% of all kidney cancer cases. It occurs when cells in the tubules of the kidneys start to grow out of control. The tubules are tube-like structures ...

Clinical Question 2 What are the preferred treatment options for second- and later-line systemic therapy for patients with advanced hepatocellular carcinoma?

Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma ...

Background Despite the success of immune checkpoint blockade, a lack of understanding of the hepatocellular carcinoma (HCC) immune microenvironment impedes its development. Objective We aim to ...

ASCO 2025 phase 1b/2 study assessing 9MW2821, nectin-4 antibody drug conjugate, toripalimab in treatment-naïve patients, locally advanced or metastatic urothelial carcinoma.

ASCO 2025, Nivolumab plus ipilimumab vs sunitinib, casdatifan plus cabozantinib, Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan, ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC) ...

Retifanlimab provides clinical benefit, with a manageable safety profile, when added to first-line chemotherapy in advanced squamous cell carcinoma of the anal canal. These results suggest ...

Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have prolonged OS. Pancreatic ...